Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension
Conditions
Interventions
Azilsartan medoxomil
Azilsartan medoxomil placebo
Locations
15
South Korea
Chuncheon, Gangwon-do, South Korea
Wŏnju, Gangwon-do, South Korea
Anyang-si, Gyeonggi-do, South Korea
Goyang-si, Gyeonggi-do, South Korea
Seongnam-si, Gyeonggi-do, South Korea
Suwon, Gyeonggi-do, South Korea
Start Date
July 1, 2014
Primary Completion Date
January 1, 2016
Completion Date
February 1, 2016
Last Updated
December 19, 2016
NCT02417740
NCT07073820
NCT07480265
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions